Table 1.
Baseline Patients’ Characteristics According to Outcomes at 1‐Year Follow‐Up
| Characteristics | No Cardiovascular Death (n=739) | Cardiovascular Death (n=75) | P Value |
|---|---|---|---|
| Risk factors | |||
| Age, y | 82 (79–86) | 85 (81–89) | 0.001 |
| Women | 380 (51) | 34 (45) | 0.394 |
| BMI <21 kg/m2 | 84 (11) | 17 (23) | 0.008 |
| Hypertension | 575 (78) | 65 (87) | 0.052 |
| Hypercholesterolemia | 367 (50) | 42 (56) | 0.244 |
| Family history of CAD | 167 (23) | 11 (15) | 0.125 |
| Diabetes mellitus | 180 (24) | 33 (44) | <0.001 |
| Smoking | 38 (5) | 5 (7) | 0.554 |
| Cardiovascular history | |||
| Stroke | 89 (12) | 16 (21) | 0.019 |
| CAD | 168 (23) | 23 (31) | 0.106 |
| Prior stroke and/or CAD | 235 (32) | 36 (48) | 0.003 |
| Heart failure | 66 (9) | 15 (20) | 0.002 |
| Chronic renal failure | 51 (7) | 11 (15) | 0.014 |
| Aortic stenosis | 77 (10) | 15 (20) | 0.011 |
| Long‐term medications | |||
| β Blockers | 296 (40) | 39 (52) | 0.035 |
| ACE inhibitors or ARBs | 378 (51) | 46 (61) | 0.071 |
| Diuretics | 150 (20) | 27 (36) | 0.001 |
| Potassium‐sparing diuretics | 25 (3) | 4 (5) | 0.371 |
| Thiazides | 130 (18) | 17 (23) | 0.251 |
| Aspirin | 242 (33) | 33 (44) | 0.040 |
| P2Y12 receptor antagonists | 104 (14) | 15 (20) | 0.150 |
| Statin | 235 (32) | 32 (43) | 0.046 |
| Biological data | |||
| CKD‐eGFR <60 mL/min per 1.73 m² | 365 (49) | 49 (65) | 0.007 |
| NT‐proBNP, pg/mL | 1790 (528–5234) | 5510 (3050–14 705) | <0.001 |
| Troponin I peak, μg/L | 6.8 (1.7–32.0) | 7.3 (2.2–49) | 0.231 |
| CRP >3 mg/L | 486 (66) | 65 (87) | <0.001 |
| Clinical data | |||
| CCI class | |||
| CCI‐0 (0) | 248 (34) | 10 (13) | 0.001 |
| CCI‐1 (1–2) | 288 (39) | 31 (41) | |
| CCI‐2 (3–4) | 116 (16) | 17 (23) | |
| CCI‐3 (>5) | 87 (12) | 16 (21) | |
| HR at admission, beats/min | 79 (69–90) | 88 (70–103) | 0.006 |
| SBP, mm Hg | |||
| At admission | 143 (123–160) | 130 (115–150) | 0.002 |
| aSBP <125 mm Hg | 344 (47) | 46 (61) | 0.010 |
| DBP, mm Hg | |||
| At admission | 76 (65–74) | 70 (63–84) | 0.269 |
| Heart failure at admission | 71 (10) | 14 (19) | 0.013 |
| STEMI | 281 (38) | 27 (36) | 0.795 |
| LVEF <40% | 112 (15) | 30 (40) | <0.001 |
| Length of ICU stay, d | 4 (3–5) | 4 (3–6) | 0.278 |
| GRACE risk score at discharge | 137 (126–150) | 153 (139–173) | <0.001 |
| Time to admission, min | 209 (105–600) | 270 (89–1005) | 0.507 |
| Heart failure in hospital | 105 (14) | 25 (33) | <0.001 |
Data are given as median (interquartile range) or number (percentage). ACE indicates angiotensin‐converting enzyme; ARB, angiotensin receptor blocker; aSBP, average SBP; BMI, body mass index; CAD, coronary artery disease (including unstable angina, myocardial infarction, coronary artery bypass grafting, and percutaneous coronary intervention); CCI, Charlson Comorbidity Index; CKD, chronic kidney disease; CRP, C‐reactive protein; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; GRACE, Global Registry of Acute Coronary Events; HR, heart rate; ICU, intensive care unit; LVEF, left ventricular ejection fraction; NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide; SBP, systolic blood pressure; STEMI, ST‐segment–elevation myocardial infarction.